Physician profile
Sonya Sheth
NPI 1144398645
$7,295.24
in general payments reported to CMS, 2019-2025
24 companies · $2,411 in 2025
The $2,411 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $84.51 · 2021: $715 · 2022: $324 · 2023: $601 · 2024: $1,541 · 2025: $2,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,473 · Travel and Lodging: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.97 |
| Travel and Lodging | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,055.33 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $903.48 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $850.95 | 2019 | |
| Bausch & Lomb Americas INC. | $732.36 | 2022-2025 | Infuse, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $672.92 | 2020-2025 | Cequa |
| Abbvie INC. | $602.71 | 2022-2025 | |
| Amgen INC. | $352.55 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $312.00 | 2019-2025 | |
| Glaukos Corporation | $299.18 | 2021-2024 | Ce-Marked Kxla System, Istent Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $278.93 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $256.86 | 2019-2021 | |
| Rxsight INC | $212.54 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $142.01 | 2019 | |
| Galderma Laboratories, L.P. | $131.69 | 2021 | |
| Dompe US, INC. | $115.42 | 2021-2025 | Oxervate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $95.87 | 2021 | |
| Thea Pharma INC. | $87.45 | 2023-2025 | Iyuzeh |
| Horizon Therapeutics Plc | $47.08 | 2023 | Tepezza |
| Shire North American Group INC | $39.77 | 2019 | |
| Oyster Point Pharma, INC. | $28.75 | 2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $25.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.85 | 2019 | |
| Coopervision INC. | $16.52 | 2023 | Misight Contact Lens |
| Kala Pharmaceuticals, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.